Goldman Sachs Group Inc Citius Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,186,559 shares of CTXR stock, worth $439,026. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,186,559
Previous 87,485
1256.3%
Holding current value
$439,026
Previous $78,000
782.05%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CTXR
# of Institutions
70Shares Held
30.6MCall Options Held
24.7KPut Options Held
0-
Armistice Capital, LLC New York, NY10.2MShares$3.76 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$2.34 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$758,0780.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$668,1180.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.65MShares$609,1290.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $54.1M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...